National Summary Results by fields of operation

Total sectors. Biotechnology results by main variables and fields of operation.

Units:

Select values to consult
- Main variables
  Values that contain
  
  Selected:61
  
  Total:61
- Fields of operation
  Values that contain
  
  Selected:1
  
  Total:5

Choose format of the table

	Fields of operation
Main variables	.	.	.
	.	.	.
	.	.	.

Decimals to show:

Notes
- 1) '..'=data not available
  
  '.'=numeric piece of data equal to zero not resulting from rounding
  
  FTE: Full Time Equivalent
  
  (*) Total calculated from the total number of companies with related activities with Biotechnology and the total Companies from other sectors with activities in R&D in Biotechnology

Total: 0seriesy 0cells

Source:National Statistics Institute

Companies that perform R+D in Biotechnology
%Companies according to biotechnology used: Genetic code
%Companies according to biotechnology used: Functional Companies
%Companies according to biotechnology used: Cellular and tissue culturing and engineering
%Companies according to biotechnology used: Bioprocesses
%Companies according to biotechnology used: Sub-cellular organisms
%Companies according to biotechnology used: Bio-computing
%Companies according to biotechnology used: Nanobiotechnology
%Companies according to biotechnology used: Other
Companies in which biotechnology activities are: Main and/or exclusive
Companies in which biotechnology activities are: A secondary line of business
Companies in which biotechnology activities are: A tool necessary for production
%Companies by field(s) of ultimate application of biotechnology use: Human health
%Companies by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture
%Companies by field(s) of ultimate application of biotechnology use: Food products
%Companies by field(s) of ultimate application of biotechnology use: Agriculture and forest production:
%Companies by field(s) of ultimate application of biotechnology use: Environment
%Companies by field(s) of ultimate application of biotechnology use: Industry
Personnel in R&D in biotechnology (no. of persons)
Personnel in R&D in biotechnology (no. of persons): Researchers
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants
Personnel in R&D in biotechnology (no. of persons): women
Personnel in R&D in biotechnology (no. of persons): (women) Researchers
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants
Personnel in R&D in biotechnology (FTE)
Personnel in R&D in biotechnology (FTE): Researchers
Personnel in R&D in biotechnology (FTE): Technicians and assistants
Personnel in R&D in biotechnology (FTE): women
Personnel in R&D in biotechnology (FTE): (women) Researchers
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants
Internal expenditure on R&D (thousands of euros)
1) By nature of the expense: Current expenses
1.1) Remuneration to researchers
1.2) Remuneration to technicians and assistants
1.3) Other current expenses
2) By nature of the expense: Capital expenses
2.1) Land and buildings
2.2) Equipment and instruments
2.3) Acquisition of specific R+D software
2.4) Otros productos de propiedad intelectual específicos para I+D
1.1) By origin of the funds: Own funds
1.2) By origin of the funds: From companies
1.3) By origin of the funds: Public Administration funds
1.4) By origin of the funds: From Universities
1.5) By origin of the funds: From non profit private institutions
1.6) By origin of the funds: Foreign funds
Purchase of services R & D in Biotechnology to (thousands of euros)
Purchase of services R & D in Biotechnology to (thousands of euros): in Spain
Purchase of services R & D in Biotechnology to (thousands of euros): Abroad
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and marketing channels
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting
%Companies that have requested biotechnology patents in Biotechnology
Number of patents requested

Total 2019
Companies
P.A.
Higher Education
PNPI